ABSTRACT
Background Emerging evidence suggests brain white matter alterations in adolescents with early-onset psychosis (EOP; age of onset <18 years). However, as neuroimaging methods vary and sample sizes are modest, results remain inconclusive. Using harmonized data processing protocols and a mega-analytic approach, we compared white matter microstructure in EOP and healthy controls (CTR) using diffusion tensor imaging (DTI).
Methods Our sample included 321 adolescents with EOP (mean age: 16.3 ± 1.4 years, 46.4% females) and 265 adolescent CTR (mean age: 16.0 ± 1.7 years, 57.7% females) pooled from nine sites. All sites extracted mean fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) for 25 white matter regions of interest per participant. ComBat harmonization was performed for all DTI measures to adjust for scanner differences. Multiple linear regression models were fitted to investigate case-control differences and associations with clinical variables in regional DTI measures.
Results We found widespread lower FA in EOP compared to CTR, with the largest effect sizes in the superior longitudinal fasciculus (Cohen’s d = 0.37), posterior corona radiata (d = 0.32), and superior fronto□occipital fasciculus (d = 0.31). We also found widespread higher RD and more localized higher MD and AD. We detected significant effects of diagnostic subgroup, sex, and duration of illness, but not medication status.
Conclusion Using the largest EOP DTI sample to date, our findings suggest a profile of widespread white matter microstructure alterations in adolescents with EOP, most prominently in male patients with early-onset schizophrenia and patients with a shorter duration of illness.
Competing Interest Statement
For work unrelated to the contents of this manuscript, the following authors received funding from third-parties. Celso Arango: has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda; Michael Berk: was supported by an unrestricted grant from AstraZeneca; Covadonga M. Dìaz-Caneja: has received honoraria from Exeltis and Angelini; Gisela Sugranyes has received honoraria from Angelini; Paul M. Thompson, Neda Jahanshad: MPI of a research grant from Biogen, Inc.; Ole A. Andreassen: has received speaker's honorarium from Lundbeck and is a consultant to HealthLytix.
Funding Statement
ENIGMA Core: U.S. National Institutes of Health grants, R01 EB015611, U54 EB020403, R01 MH116147, R01 MH117601, R01 MH121246, S10 OD023696. YTOP: The Research Council of Norway (#223273, #2137000, #250358, #288083); South-Eastern Norway Regional Health Authority (#2017112); KG Jebsen Stiftelsen (#SKGJ-MED-008). MADRID: Celso Arango has received funding from CIBERSAM: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, co-financed by ERDF Funds from the European Commission; CIBERSAM; Instituto de Investigación Sanitaria Gregorio Marañón; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2, Youth Employment Operational Program and Youth Employment Initiative); European Social Fund and EU Structural Funds; EU Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-602478, and FP7-HEALTH-2013-2.2.1-2-603196; EU H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. Covadonga M. Díaz-Cenaj has received grant support from Instituto de Salud Carlos III (PI17/00481, PI20/00721, JR19/00024). FEMS: This project was supported by an unrestricted grant from AstraZeneca. Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). SCAPS: The Swedish Research Council (#521-2014-3487, #2017-00949); FORMAS (#259-2012-31). OXFORD: MRC G0500092. MEND: NIMH R01 MH101506. PAFIP: This study was supported by grants from Carlos III Health Institute (IPI17/00402, PI17/01056, PI14/00639 and PI14/00918) cofunded by The European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. BARCELONA: Elena de la Serna has received grant support from Instituto de Salud Carlos III (PI20/00654). Gisela Sugranyes has received research funds from Instituto de Salud Carlos III (PI1800976 and PI2100330), the Alicia Koplowitz Foundation (AKOPLOWITZ20_004), Ajut a la Recerca Pons Bartran (FCRB_PB1_2018) and a Brain and Behaviour Research Foundation NARSAD 2017 Young Investigator Grant (26731). UCLA: NIMH grants U01MH081902, P50MH066286.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ENIGMA-EOP Working Group obtained case-control data from nine cohorts across seven countries. The study was coordinated by Claudia Barth and Ingrid Agartz, who got approval for this work by the Norwegian Regional Committees for Medical and Health Research Ethics (REK, Number: 2009/691). For each site, all study participants and/or their legal guardians provided written informed consent with approval from local institutional review boards and the respective ethics committees.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
